Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | LSS | P48449 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24721280 | 1.00 | SIGMAR1 (0.42) | SIGMAR1PIM1LSSATML3MBTL1 | |
| SCHEMBL13935740 | 1.00 | SIGMAR1 (0.42) | SIGMAR1PIM1LSSATML3MBTL1 | |
| SCHEMBL10202195 | 0.93 | SIGMAR1 (0.38) | SIGMAR1PIM1LSS | |
| SCHEMBL172541 | 0.85 | — | — | |
| SCHEMBL81996 | 0.85 | — | — | |
| SCHEMBL172592 | 0.85 | — | — | |
| SCHEMBL24595298 | 0.81 | SIGMAR1 (0.35) | SIGMAR1PIM1LSS | |
| SCHEMBL10202192 | 0.81 | L3MBTL3 (0.37) | L3MBTL1HTR2A | |
| SCHEMBL13860754 | 0.79 | SIGMAR1 (0.38) | SIGMAR1LSSATML3MBTL1SMN1; SMN2 | |
| SCHEMBL13456607 | 0.77 | SIGMAR1 (0.37) | SIGMAR1ATML3MBTL1SMN1; SMN2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269737-A1 | 7-(Piperazine-1-Ymethyl)-1H-Indole-2-Carboxylic Acid (Phenyl)-Amide Derivatives and Allied Compounds as P38 Map Kinase Inhibitors for the Treatment of Respiratory Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | claimed |
| EP-2323980-A1 | 7-(PIPERAZINE-1-YMETHYL)-1H-INDOLE-2-CARBOXYLIC ACID (PHENYL)-AMIDE DERIVATIVES AND ALLIED COMPOUNDS AS P38 MAP KINASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2011-05-25 | — | — | EP | claimed |
| WO-2010026096-A1 | 7-(PIPERAZINE-1-YMETHYL)-1H-INDOLE-2-CARBOXYLIC ACID (PHENYL)-AMIDE DERIVATIVES AND ALLIED COMPOUNDS AS P38 MAP KINASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | claimed |
| WO-2024081363-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024062250-A1 | IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS | BENEVOLENTAI BIO LIMITED (GB) | 2024-03-28 | — | — | WO | disclosed |
| EP-4306520-A1 | THIOPHENE COMPOUND AND APPLICATION THEREOF | Medshine Discovery Inc. (CN) | 2024-01-17 | — | — | EP | disclosed |
| EP-4279486-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | Guangzhou Salustier Biosciences Co., Ltd. (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| WO-2023082052-A1 | CYCLIC 2-AMINOPYRIMIDINE COMPOUND AND APPLICATION THEREOF | 暨南大学 | 2023-05-19 | — | — | WO | disclosed |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | ASTELLAS PHARM INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-2025675-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2009-02-18 | — | — | EP | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20080081811-A1 | Selective Inhibitors Against Cdk4 and Cdk6 Having Aminothiazole Skeleton | BANYU PHARMACEUTICAL CO., LTD (JP) | 2008-04-03 | — | — | US | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| CN-1956982-A | Selective inhibitors against Cdk4 and Cdk6 having aminothiazole skeleton | BANYU PHARMA CO LTD (JP) | 2007-05-02 | — | — | CN | disclosed |
| EP-1754706-A1 | SELECTIVE INHIBITORS AGAINST Cdk4 AND Cdk6 HAVING AMINOTHIAZOLE SKELETON | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-21 | — | — | EP | disclosed |
| CN-1258294-A | 2-oxoimidazole derivs. | BANYU PHARMA CO LTD (JP) | 2000-06-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | SIGMAR1 113/4885PIM1 1163/4885LSS 3975/4885 |
| US-20110269737-A1 | 7-(Piperazine-1-Ymethyl)-1H-Indole-2-Carboxylic Acid (Phenyl)-Amide Derivatives and Allied Compounds as P38 Map Kinase Inhibitors for the Treatment of Respiratory Diseases | MAPKAPK2, MAPKAPK5, MAPK7 | SIGMAR1 1885/4885PIM1 256/4885LSS 3750/4885 |
| US-20080081811-A1 | Selective Inhibitors Against Cdk4 and Cdk6 Having Aminothiazole Skeleton | CDK4, CDK6, CDK3 | SIGMAR1 3663/4885PIM1 469/4885LSS 3181/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | SIGMAR1 3617/4885PIM1 837/4885LSS 2515/4885 |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | ABL1, PRKDC, PRKACA | SIGMAR1 3814/4885PIM1 107/4885LSS 4326/4885 |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | STAT6, STAT4, STAT3 | SIGMAR1 2789/4885PIM1 608/4885LSS 4696/4885 |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | MITF, PRKDC, PRKACA | SIGMAR1 4344/4885PIM1 237/4885LSS 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.